Artivion, Inc. $AORT Holdings Lowered by Perceptive Advisors LLC

Perceptive Advisors LLC trimmed its stake in shares of Artivion, Inc. (NYSE:AORT) by 14.7% in the 4th quarter, HoldingsChannel reports. The firm owned 1,722,290 shares of the company’s stock after selling 297,710 shares during the quarter. Artivion makes up about 1.4% of Perceptive Advisors LLC’s portfolio, making the stock its 23rd biggest position. Perceptive Advisors LLC’s holdings in Artivion were worth $78,554,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion during the third quarter valued at $27,000. Aster Capital Management DIFC Ltd lifted its holdings in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares during the last quarter. USA Financial Formulas lifted its holdings in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the last quarter. Finally, KBC Group NV purchased a new stake in shares of Artivion during the fourth quarter valued at $65,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by company insiders.

Artivion Stock Down 0.8%

Shares of Artivion stock opened at $21.27 on Thursday. The stock has a 50-day moving average price of $28.16 and a 200 day moving average price of $36.44. The company has a market cap of $1.03 billion, a P/E ratio of 88.63 and a beta of 1.26. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC reduced their target price on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a report on Friday, April 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 price objective on shares of Artivion in a research note on Tuesday. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.17.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.